Evidence map›Paper›PMID 34233469›Full record

ArticleThe British journal of radiology2021

Hypofractionated stereotactic body radiation therapy (SBRT) in pediatric patients: preliminary toxicity results of a national prospective multicenter study.

Dario Di Perri, Emmanuel Jouglar, Ellen Blanc, Anne Ducassou, Aymeri Huchet, Céline Vigneron, Alexandre Escande, Sophie Chapet, Julie Leseur, Valérie Bernier and 3 more

Abstract readMulticenter Study
In one paragraph

Article in The British journal of radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Bridging surgery and radiotherapy: the role of stereotactic radiosurgery in pediatric brain tumor care.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Pooled it
  2. Tumor ablation in children.Pediatric radiology · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dario Di PerriDepartment of radiation oncology, Centre Léon Bérard, Lyon, France.ORCID https://orcid.org/0000-0001-7997-3865
Emmanuel JouglarDepartment of radiation oncology, Institut de Cancérologie de l'Ouest, Nantes, France.
Ellen BlancDepartment of clinical research and innovation, Centre Léon Bérard, Lyon, France.
Anne DucassouDepartment of radiation oncology, Institut Claudius Regaud, IUCT-Oncopôle, Toulouse, France.
Aymeri HuchetDepartment of radiation oncology, Centre Hospitalier Universitaire, Bordeaux, France.
Céline VigneronDepartment of radiation oncology, Centre Paul Strauss, Strasbourg, France.
Alexandre EscandeDepartment of radiation oncology, Centre Oscar Lambret, Lille, France.
Sophie ChapetDepartment of radiation oncology, Centre Hospitalier Universitaire, Tours, France.
Julie LeseurDepartment of radiation oncology, Centre Eugène Marquis, Rennes, France.
Valérie BernierDepartment of radiation oncology, Institut de Cancérologie de Lorraine, Nancy, France.
Christian CarrieDepartment of radiation oncology, Centre Léon Bérard, Lyon, France.
Valentine MartinDepartment of radiation oncology, Institut Gustave Roussy, Villejuif, France.
Line ClaudeDepartment of radiation oncology, Centre Léon Bérard, Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWhile hypofractionated stereotactic body radiotherapy (SBRT) has been largely adopted in the adult setting, its use remains limited in pediatric patients. This is due, among other factors, to fear of potential toxicities of hypofractionated regimens at a young age. In this context, we report the preliminary acute (<3 months from SBRT) and middle-term (3-24 months) toxicity results of a national prospective study investigating SBRT in pediatric patients.

methodsBetween 2013 and 2019, 61 patients were included. The first 40 patients (median age: 12 y, range: 3-20) who completed a 2-year-follow-up were included in the present analysis. SBRT was used for treating lung, brain or (para)spinal lesions, either as first irradiation (35%) or in the reirradiation setting (65%).

resultsAcute and middle-term grade ≥2 toxicities occurred in 12.5 and 7.5% of the patients, respectively. No grade ≥4 toxicities occurred. Almost all toxicities occurred in the reirradiation setting.

conclusionSBRT showed a favorable safety profile in young patients treated for lung, brain, and (para)spinal lesions. ADVANCES IN KNOWLEDGE: SBRT appeared to be safe in pediatric patients treated for multiple oncology indications. These results support further evaluation of SBRT, which may have a role to play in this patient population in the future.

Indexed as

Dose Fractionation, RadiationAdolescentAdultBrain NeoplasmsChildChild, PreschoolFemaleFranceHumansLung NeoplasmsMalePediatricsProspective StudiesRadiosurgeryRe-IrradiationSpinal Neoplasms

Identifiers

PMID34233469
PMCPMC9327744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.